Ultragenyx Pharmaceutical Inc. (RARE)

Acerca de Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Al 3 de noviembre de 2026, la acción de Ultragenyx Pharmaceutical Inc. (RARE) subió con fuerza a $16.76, un alza de 2.82% (+$0.46) frente al cierre anterior. En la sesión, las acciones han operado entre $16.39 y $16.99. Eso ubica a RARE en el tercio inferior de su rango de 52 semanas, de $12.73 a $39.89. Ultragenyx Pharmaceutical Inc. opera en el sector de pharmaceutical preparations y tiene una capitalización de mercado de aproximadamente $1.61 mil millones, con cerca de 745.3 mil acciones negociadas.

Últimas noticias de RARE

• Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?Yahoo Finance· 30 oct, 5:53 p.m. ET
• Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out forYahoo Finance· 28 oct, 9:00 a.m. ETCTKB
• GSK (GSK) Q3 Earnings and Revenues Beat EstimatesYahoo Finance· 28 oct, 6:10 a.m. ETGSK
• Has The Story Under Krystal Biotech Stock Run Out?trefis.com· 28 oct, 4:22 a.m. ET
• Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate UpdateYahoo Finance· 27 oct, 4:05 p.m. ET
• Broadcom upgraded, HubSpot downgraded: Wall Street's top analyst callsYahoo Finance· 27 oct, 9:40 a.m. ET
• Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseYahoo Finance· 27 oct, 9:00 a.m. ET
• Sector Update: Healthcare Stocks Softer Monday AfternoonYahoo Finance· 19 oct, 1:52 p.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de RARE en un solo lugar? Crea una cuenta gratis →

• $RARE NEW CORPORATE PRESENTATION

  @MrHankey69· 3 nov, 10:48 a.m. ET· Alcista

• $RARE just moving with XBI I want some good news today to go beyond

  @RonnySalts· 3 nov, 10:36 a.m. ET

• Ultragenyx $RARE terminated its Phase 2 GTX-102 Angelman study for lack of efficacy. The trial enrolled 55 patients. Q3 results are due today at 5:00 p.m. ET. Shares closed at $16.30 on Monday, below the SMA50 and below the SMA200, RSI 62. More details in our hub. Not investme…

  @Merlintrader· 3 nov, 9:06 a.m. ET

• $RARE they tell me the BIG DROP was an OVER REACTION wen the STOCK FELL by %50.well we will find out today the same day of USA ellections.CLOSE eye on aerly + last hour trades we might have some good NEWS.

  @porky1963· 3 nov, 6:01 a.m. ET

• $RARE Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday,…

  @Idontknownothing55· 2 nov, 2:21 p.m. ET· Alcista

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →